President-elect Donald Trump and Robert Kennedy, Jr. — his pick to head up the Department of Health and Human Services — were hot topics at the Jefferies …

Doctor Peter Vanderklish from Spinogenix talks about their advanced human trials in synaptic generation. Doctor Vanderklish, welcome to the program.

CEO Rajesh Devraj describes the company’s focus on membrane protein function and normalizing it with small molecules, in this case for cholestasis and cholangitis associated with liver diseases.

CEO Berndt Modig describes the science behind creating both immediate release capsuls and extended release tablets. Successfully developing an oral therapy could set Pharvaris apart.

While Anima has contributed to the scientific literature itself, with a growing list of peer-reviewed publications on protein synthesis monitoring and tRNA visualization, Slonim argues that relying solely on mining existing research isn’t enough.

Industry leaders reshaping the pharma world.

From a trial design perspective, we’ve tried to make these trials as familiar to stakeholders – regulators, prescribers, payors – as possible. What’s remarkable here are the qualities of the drug that we’re developing, MM120, a pharmaceutical formulation of LSD; we don’t need to do anything inconsistent with the history of psychiatric clinical trials beyond that.

Pharvaris is moving forward with Phase 3 clinical trials. The RAPIDe-3 study (NCT06343779) is testing an immediate-release formulation of deucrictibant, called PHVS416, as an on-demand therapy for HAE. Recruitment is ongoing at sites in the U.S., Puerto Rico, South Korea, and Germany.